Atria Wealth Solutions Inc. lifted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 9.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 15,754 shares of the medical research company's stock after purchasing an additional 1,389 shares during the period. Atria Wealth Solutions Inc.'s holdings in Thermo Fisher Scientific were worth $8,199,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds have also bought and sold shares of the company. KLCM Advisors Inc. bought a new stake in Thermo Fisher Scientific during the fourth quarter valued at $218,000. AlphaCentric Advisors LLC bought a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at about $2,172,000. Americana Partners LLC increased its holdings in Thermo Fisher Scientific by 1,217.6% in the fourth quarter. Americana Partners LLC now owns 82,809 shares of the medical research company's stock worth $43,080,000 after purchasing an additional 76,524 shares in the last quarter. Sierra Ocean LLC acquired a new position in Thermo Fisher Scientific in the fourth quarter valued at approximately $40,000. Finally, Meridiem Investment Management Ltd. grew its position in shares of Thermo Fisher Scientific by 14.4% during the 4th quarter. Meridiem Investment Management Ltd. now owns 631,856 shares of the medical research company's stock worth $328,719,000 after buying an additional 79,555 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of research analysts recently issued reports on the stock. Wells Fargo & Company boosted their target price on shares of Thermo Fisher Scientific from $660.00 to $680.00 and gave the company an "overweight" rating in a research report on Friday, January 31st. StockNews.com raised shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Tuesday, January 14th. Sanford C. Bernstein raised Thermo Fisher Scientific from a "market perform" rating to an "outperform" rating and set a $630.00 target price for the company in a research report on Friday, January 10th. Evercore ISI cut their price target on Thermo Fisher Scientific from $630.00 to $620.00 and set an "outperform" rating on the stock in a report on Thursday, October 24th. Finally, Bank of America decreased their price objective on Thermo Fisher Scientific from $675.00 to $660.00 and set a "buy" rating for the company in a report on Friday, December 13th. Four investment analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $658.00.
View Our Latest Stock Analysis on TMO
Insider Activity at Thermo Fisher Scientific
In related news, CFO Stephen Williamson sold 9,825 shares of the stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $5,753,421.75. Following the sale, the chief financial officer now owns 27,296 shares of the company's stock, valued at approximately $15,984,264.64. This represents a 26.47 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Gianluca Pettiti sold 300 shares of the company's stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $175,677.00. Following the sale, the executive vice president now owns 16,363 shares in the company, valued at approximately $9,582,009.17. This represents a 1.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 20,125 shares of company stock worth $11,231,699. Company insiders own 0.34% of the company's stock.
Thermo Fisher Scientific Stock Performance
Shares of NYSE TMO traded down $5.28 during mid-day trading on Friday, reaching $532.55. 1,613,862 shares of the company's stock were exchanged, compared to its average volume of 2,087,588. The firm has a market capitalization of $203.70 billion, a price-to-earnings ratio of 32.22, a price-to-earnings-growth ratio of 2.95 and a beta of 0.77. The firm has a 50-day moving average price of $548.36 and a two-hundred day moving average price of $568.15. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. Thermo Fisher Scientific Inc. has a 52 week low of $493.30 and a 52 week high of $627.88.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, beating analysts' consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. Analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.
Thermo Fisher Scientific Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th will be paid a dividend of $0.43 per share. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.39. The ex-dividend date is Friday, March 14th. This represents a $1.72 annualized dividend and a dividend yield of 0.32%. Thermo Fisher Scientific's dividend payout ratio is presently 9.44%.
Thermo Fisher Scientific declared that its board has authorized a stock repurchase program on Friday, November 15th that permits the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization permits the medical research company to buy up to 2% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company's board believes its stock is undervalued.
About Thermo Fisher Scientific
(
Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Featured Articles
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
